NKTR 241115 1.00C (NKTR241115C1000) Stock Options, News & Quotes

$Nektar Therapeutics (NKTR.US)$
SAN FRANCISCO, Oct. 29, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of rezpegaldesleukin in patients with atopic dermatitis (AD) and psoriasis (PsO).
Rezpegal...

Jaimevq14

Oct 29 08:23

Share Your Profit/Loss

Trytosaveabit

Oct 29 08:14

Update

$Nektar Therapeutics (NKTR.US)$ Data From Nektar's Multiple Phase 1b Studies In Inflammatory Skin Conditions Demonstrate Durable Dose-dependent Improvements In Physician-assessed Disease Activity And Patient-reported Outcomes
Benzinga· 1 min ago
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated ...

Jaguar8

Oct 29 08:02

NEWS

$Nektar Therapeutics (NKTR.US)$ m
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
Nektar Therapeutics (NKTR) published peer-reviewed data from two Phase 1b studies in Nature Communications showing promising results for rezpegaldesleukin in treating atopic dermatitis (AD) and psoriasis (PsO). The studies demonstrated that the drug safely increased regulatory T cells (Tregs) and improved disease outcom...